Reported Tuberculosis in the United States, 2017

Return to Main Menu

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20151

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2015
Reporting Area Total Cases Therapy ≤1 year indicated2,3,4 Therapy >1 year indicated3,5
No. COT ≤1 year(%) COT(%) No. COT(%)
United States 9,547 7,860 (89.5) (95.8) 519 (90.2)
Alabama 119 98 (85.7) (95.9) 6 (100.0)
Alaska 68 59 (93.2) (100.0) 5 (100.0)
Arizona 198 151 (92.1) (98.0) 9 (88.9)
Arkansas 90 79 (84.8) (96.2) 4 (100.0)
California 2,131 1,764 (88.2) (95.4) 105 (87.6)
Colorado 73 61 (95.1) (96.7) 6 (100.0)
Connecticut 70 56 (94.6) (100.0) 6 (100.0)
Delaware 22 18 (88.9) (100.0) 2 (100.0)
District of Columbia 33 24 (87.5) (95.8) 2 (100.0)
Florida 602 496 (95.6) (98.4) 34 (88.2)
Georgia 320 270 (90.4) (97.8) 17 (100.0)
Hawaii 127 113 (95.6) (99.1) 6 (100.0)
Idaho 11 9 (100.0) (100.0) 1 (100.0)
Illinois 343 289 (94.5) (98.6) 15 (100.0)
Indiana 116 101 (94.1) (96.0) 5 (100.0)
Iowa 38 34 (85.3) (91.2) 1 (100.0)
Kansas 36 32 (93.8) (96.9) 3 (66.7)
Kentucky 67 53 (94.3) (100.0) 7 (100.0)
Louisiana 119 107 (65.4) (72.9) 4 (75.0)
Maine 18 15 (100.0) (100.0) 1 (100.0)
Maryland 176 141 (90.8) (98.6) 14 (92.9)
Massachusetts 192 151 (88.7) (97.4) 15 (93.3)
Michigan 131 112 (95.5) (99.1) 4 (100.0)
Minnesota 150 125 (95.2) (97.6) 15 (93.3)
Mississippi 73 55 (89.1) (96.4) 3 (100.0)
Missouri 92 77 (81.8) (88.3) 5 (80.0)
Montana 9 7 (100.0) (100.0) 1 (100.0)
Nebraska 33 27 (37.0) (37.0) 3 (0.0)
Nevada 85 71 (94.4) (98.6) 3 (100.0)
New Hampshire 13 7 (100.0) (100.0) 3 (100.0)
New Jersey 326 254 (90.9) (97.2) 20 (85.0)
New Mexico 47 29 (93.1) (96.6) 2 (100.0)
New York State6 188 149 (94.0) (97.3) 12 (83.3)
New York City 575 489 (94.1) (98.0) 35 (97.1)
North Carolina 199 162 (92.6) (99.4) 12 (100.0)
North Dakota 9 7 (85.7) (85.7) 0
Ohio 143 116 (83.6) (93.1) 6 (100.0)
Oklahoma 67 59 (88.1) (96.6) 0
Oregon 76 64 (89.1) (95.3) 5 (100.0)
Pennsylvania 200 165 (80.6) (93.3) 5 (100.0)
Rhode Island 30 23 (100.0) (100.0) 2 (100.0)
South Carolina 104 86 (91.9) (94.2) 4 (100.0)
South Dakota 17 14 (50.0) (78.6) 0
Tennessee 131 106 (95.3) (96.2) 10 (90.0)
Texas 1,334 1,089 (87.5) (94.5) 70 (82.9)
Utah 37 31 (93.5) (96.8) 5 (100.0)
Vermont 7 7 (100.0) (100.0) 0
Virginia 212 180 (92.2) (97.2) 10 (100.0)
Washington 207 162 (74.1) (90.1) 13 (76.9)
West Virginia 10 6 (83.3) (100.0) 1 (0.0)
Wisconsin 69 58 (86.2) (100.0) 2 (50.0)
Wyoming 4 2 (100.0) (100.0) 0
American Samoa7 4 4 (0.0) (0.0) 0
Fed. States of Micronesia7 103 93 (90.3) (91.4) 2 (50.0)
Guam7 76 66 (60.6) (62.1) 3 (66.7)
Marshall Islands7 136 118 (87.3) (91.5) 2 (100.0)
N. Mariana Islands7 27 25 (80.0) (88.0) 1 (100.0)
Puerto Rico7 52 38 (73.7) (86.8) 2 (100.0)
Republic of Palau7 14 11 (90.9) (90.9) 2 (100.0)
U.S. Virgin Islands7 0

1 Most recent year for which data are available.
2 Initial isolate susceptible to rifampin (n = 5,915) or susceptibility unknown (n = 74); culture negative (n = 1,566); culture status unknown (n = 305).
3 Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia).
4 Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment.
5 Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6 Excludes New York City.
7 Not included in U.S. totals.
Note: Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes for description of completion of therapy calculation.

Page last reviewed: October 22, 2018